Get the Stockscreener App
0.5431
3.88%
0.0205
Elevation Oncology Inc stock is traded at $0.5431, with a volume of 276.63K.
It is up +3.88% in the last 24 hours and up +0.84% over the past month.
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
See More
Previous Close:
$0.5226
Open:
$0.53
24h Volume:
276.63K
Relative Volume:
0.24
Market Cap:
$30.89M
Revenue:
-
Net Income/Loss:
$-39.35M
P/E Ratio:
-0.1517
EPS:
-3.58
Net Cash Flow:
$-48.92M
1W Performance:
-8.45%
1M Performance:
+0.84%
6M Performance:
-85.33%
1Y Performance:
+21.97%
1-Day Range:
$0.525
$0.548
1-Week Range:
$0.5221
$0.6341
52-Week Range:
$0.363
$5.8299
Elevation Oncology Inc Stock (ELEV) Company Profile
Name
Elevation Oncology Inc
Sector
Industry
Phone
(716) 371-1125
Address
101 FEDERAL STREET, BOSTON
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
Elevation Oncology Inc Stock (ELEV) Latest News
Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - Yahoo Finance
Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News
Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex
It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News
Elevation Oncology Inc (ELEV)’s stock price range in the last year - US Post News
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock - MSN
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
In the Green: Elevation Oncology Inc (ELEV) Closes at 0.52, Up/Down -3.69 from Previous Day - The Dwinnex
Taking on analysts’ expectations and winning: Elevation Oncology Inc (ELEV) - SETE News
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Market Momentum Report: Elevation Oncology Inc (ELEV)’s Positive Close at 0.59 - The Dwinnex
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readouts - Investing.com
Should investors be concerned about Elevation Oncology Inc (ELEV)? - US Post News
Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Elevance Health Inc [ELV] PERU RAMIRO G sells 753 Shares for $0.4 million - Knox Daily
Check out these key findings about Elevation Oncology Inc (ELEV) - SETE News
Lombard Odier Asset Management Europe Ltd Invests $2.51 Million in Elevance Health, Inc. (NYSE:ELV) - Defense World
FDA grants fast track designation for Elevation Oncology’s EO-3021 - Pharmaceutical Business Review
Pacer Advisors Inc. Decreases Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Distillate Capital Partners LLC Grows Position in Elevance Health, Inc. (NYSE:ELV) - MarketBeat
Study Underscores Importance of Medicaid Coverage for Pregnant Women - Healthcare Innovation
Elevai Labs shares tumble on pricing of new stock offering - The Business Journals
Elevance Health, Inc. (NYSE:ELV) Position Boosted by Magnetar Financial LLC - Defense World
Decoding Elevance Health's Options Activity: What's the Big Picture? - Benzinga
ELAB’s price-to-free cash flow ratio: What it means for investors - US Post News
Ratios in Focus: Analyzing Elevation Oncology Inc (ELEV)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Why Elevai Labs (ELAB) Stock Is Down 60% Today - Benzinga
Investing in Elevation Oncology Inc (ELEV) might be a great opportunity, but the stock is a bit undervalued - US Post News
Baltic Fintech Eleving To Raise Up To €30M In IPO - Law360
FDA grants fast track to Elevation Oncology's cancer drug - Investing.com
Ensign Peak Advisors Inc Acquires 2,862 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering - GlobeNewswire
Elevation Oncology Gets FDA Fast-Track Designation for EO-3021 - MarketWatch
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - StockTitan
Eleving Group Targets $34 Million From Initial Public Offering - MarketWatch
Fidelis Capital Partners LLC Acquires 1,168 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
1832 Asset Management L.P. Sells 5,622 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Frank Rimerman Advisors LLC Raises Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevance Health, Inc. (NYSE:ELV) Stock Position Decreased by Sompo Asset Management Co. Ltd. - Defense World
Sound Shore Management Inc. CT Sells 32,574 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Callan Capital LLC Buys 391 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Blair William & Co. IL Has $8 Million Position in Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevation Oncology faces Nasdaq delisting over low stock price - Investing.com
Bradley Foster & Sargent Inc. CT Sells 25 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World
Elevation Oncology faces Nasdaq delisting over low stock price By Investing.com - Investing.com Australia
Elevance Health, Inc. (NYSE:ELV) Shares Bought by Benjamin Edwards Inc. - Defense World
Elevation Oncology Inc Stock (ELEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):